BioSpace News Archive

UL Solutions Inc. (“UL Solutions” or the “Company”) (NYSE: ULS), a global safety science leader in independent third-party testing, inspection and certification services and related software and advisory offerings, today reported results for the first quarter ended March 31, 2024.

Cerevance announced that Craig Thompson, chief executive officer, will participate in a panel at the 2024 BIO International Convention, taking place in San Diego, CA from June 3 – 6, 2024.

Biora Therapeutics, Inc. presented a poster titled “Results of human device function studies for the NaviCap™ Targeted Oral Delivery Platform in healthy volunteers and patients with UC” at the Digestive Disease Week® conference in Washington DC, on Sunday, May 19, 2024.

Volta Medical announced positive results from the transatlantic, multicenter, randomized, controlled, superiority trial titled Tailored vs. Anatomical Ablation Strategy for Persistent Atrial Fibrillation (TAILORED-AF) at Heart Rhythm 2024 Late Breaking Clinical Trials and Science program.

Spinogenix, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to SPG601 for the treatment of Fragile X Syndrome (FXS).

Scorpius Holdings, Inc, an integrated contract development and manufacturing organization, announced a significant expansion of its operational footprint in San Antonio, Texas, with the opening of its new, state-of-the-art storage and testing facility.

Inhibikase Therapeutics, Inc. today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 1,672,452 shares of common stock (or pre-funded warrants in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules.

ENDRA Life Sciences Inc., a pioneer of Thermo Acoustic Enhanced UltraSound, announced that it has completed what it considers to be a highly informative pre-submission meeting with the U.S. Food and Drug Administration related to the clinical trial design of the TAEUS liver device in support of its U.S. De Novo filing.

Avenacy today announced it has launched Isoproterenol Hydrochloride Injection, USP in the United States as a therapeutic generic equivalent for ISUPREL ® as approved by the U.S. Food and Drug Administration.

Exelixis, Inc. (Nasdaq: EXEL) today announced that it has entered into a Settlement and License Agreement (Agreement) with Cipla Ltd. and Cipla USA, Inc. (collectively Cipla).